SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending due to the commencement of volume shipments of its NVIDIA Blackwell Ultra systems, a development sparking bullish sentiment among investors. The community is actively discussing the potential for earnings revisions and a stock re-rating, while also weighing the company's historical compliance issues. Some believe the stock is undervalued with substantial upside, while others remain cautious.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending as community members discuss potential short squeezes and a recent partnership with Narval Holding Corp to launch an AI-powered cargo security management solution in Panama. Bullish investors express confidence despite a recent earnings dip, anticipating future growth and contract wins in the AI and security sector. Some traders are eyeing specific price points and potential gap closures, while others are focused on long-term prospects.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors discuss the company's AI strategy and recent financial performance, including raised guidance. Community members are weighing the potential impact of AI on Adobe's growth and debating whether the stock's valuation reflects its future prospects, while considering analyst ratings and price targets.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

QMMM is trending due to speculation around its potential as a crypto play, drawing comparisons to previous high-flying stocks in the sector. Community chatter suggests the stock's low float and crypto treasury plans are attracting attention, with some anticipating a possible short squeeze. However, some users are wary, viewing it as a potential pump and dump scheme.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI.X is trending as community members are rolling profits into the coin, anticipating a breakout and a broader meme cycle on the Solana network. The community emphasizes the coin's strong community-driven growth and potential as a culture coin, drawing comparisons to other popular meme coins.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential acquisition by Paramount Skydance, fueled by a mostly cash offer backed by the Ellison family, which has sent shares soaring. The community is buzzing about potential bidding wars and the impact on streaming rivals like Netflix, while analysts estimate a potential buyout offer between $20-$30. Chatter also includes speculation of a large options trade ahead of the news, and what a combined PSKY/WBD company could be worth.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to positive study results for its continuous blood glucose monitor. The community is focused on the stock's low float and potential for a short squeeze, while some caution about its history of reverse splits and dilution. Discussions also highlight the potential for a multi-day run and the possibility of a partnership announcement.

TON Strategy Co. engages in platform development. The firm's Software-as-a-Service (SaaS) platform is based on its proprietary interactive video technology and consists of a suite of sales enablement business software products offered on a subscription basis. The company was founded by Rory J. Cutaia on November 27, 2012 and is headquartered in Las Vegas, NV.

TON Strategy Co.

TON Strategy is trending due to a recently announced $250M share buyback program and the initiation of Toncoin staking operations, sparking mixed reactions within the community. Some investors view the buyback as a positive sign given the company's cash reserves, while others express skepticism, drawing comparisons to past strategies and expressing concerns about potential dilution. The company's shift towards crypto and its association with the Telegram Open Network (TON) ecosystem are also central talking points.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The stock is trending amid community discussion surrounding the fatal shooting of Charlie Kirk, a conservative activist, with community members offering diverse perspectives and theories. Some users are using the event to launch political attacks, while others are sharing news updates and expressing concerns about societal divisions. Additionally, the release of the Epstein files is a recurring theme in the conversation.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending due to community excitement around its potential in treating liver diseases, particularly MASH cirrhosis, and speculation about a possible buyout. Bullish investors express confidence, citing insider ownership and promising data, while also noting a high short interest that could lead to a significant short squeeze. Concerns remain about potential short-term volatility and the need for continued positive developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences Announces Completion of Acquisition of CymaBay

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in...

CymaBay Therapeutics (CBAY, $32.48) Aroon Indicator entered an Uptrend on March 21, 2024.

Over the last three days, A.I.dvisor has detected that CBAY's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

CymaBay Therapeutics (CBAY, $32.47) Aroon Indicator entered an Uptrend on March 20, 2024.

CymaBay Therapeutics (CBAY, $32.48) Aroon Indicator entered an Uptrend on March 19, 2024.

CymaBay Therapeutics (CBAY, $32.48) Aroon Indicator entered an Uptrend on March 18, 2024.

CymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY  Get Free Report) in a research note issued to investors on Sunday. The brokerage set a...

CymaBay Therapeutics (CBAY, $32.45) Aroon Indicator entered an Uptrend on March 15, 2024.

CymaBay Therapeutics (CBAY, $32.47) Aroon Indicator entered an Uptrend on March 14, 2024.

CymaBay Therapeutics (CBAY, $32.44) Aroon Indicator entered an Uptrend on March 13, 2024.

CymaBay Therapeutics (CBAY, $32.45) Aroon Indicator entered an Uptrend on March 12, 2024.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.  Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenateâ??s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Current Price	$32.48
Prev Close	$32.47
Open	$32.49
Dividend Yield	0.00%
50-Day Moving Average	$29.45
Beta	0.94
Avg. Volume	7.81M
PE Ratio	-32.75

52-Week High	$32.50
52-Week Low	$7.26
Market Capitalization	$3.73B
EPS (Annual)	-$0.9919
Price to Book	12.65
Revenue Per Employee	$307,653.47
Enterprise Value/EBITDA	-23.73

CBAY
Cymabay Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CBAY News

CBAY Cymabay Therapeutics Inc